175 related articles for article (PubMed ID: 28551847)
1. Prior malignancies in patients harboring glioblastoma: an institutional case-study of 2164 patients.
Zacharia BE; DiStefano N; Mader MM; Chohan MO; Ogilvie S; Brennan C; Gutin P; Tabar V
J Neurooncol; 2017 Sep; 134(2):245-251. PubMed ID: 28551847
[TBL] [Abstract][Full Text] [Related]
2. Giant cell glioblastoma: a glioblastoma subtype with distinct epidemiology and superior prognosis.
Kozak KR; Moody JS
Neuro Oncol; 2009 Dec; 11(6):833-41. PubMed ID: 19332771
[TBL] [Abstract][Full Text] [Related]
3. Prior malignancy impact on survival outcomes of glioblastoma multiforme; population-based study.
Al-Husseini MJ; Saad AM; El-Shewy KM; Nissan NE; Gad MM; Alzuabi MA; Samir Alfaar A
Int J Neurosci; 2019 May; 129(5):447-454. PubMed ID: 30366515
[TBL] [Abstract][Full Text] [Related]
4. Long-term glioblastoma multiforme survivors: a population-based study.
Scott JN; Rewcastle NB; Brasher PM; Fulton D; Hagen NA; MacKinnon JA; Sutherland G; Cairncross JG; Forsyth P
Can J Neurol Sci; 1998 Aug; 25(3):197-201. PubMed ID: 9706720
[TBL] [Abstract][Full Text] [Related]
5. The influence of maximum safe resection of glioblastoma on survival in 1229 patients: Can we do better than gross-total resection?
Li YM; Suki D; Hess K; Sawaya R
J Neurosurg; 2016 Apr; 124(4):977-88. PubMed ID: 26495941
[TBL] [Abstract][Full Text] [Related]
6. Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
Babu R; Komisarow JM; Agarwal VJ; Rahimpour S; Iyer A; Britt D; Karikari IO; Grossi PM; Thomas S; Friedman AH; Adamson C
J Neurosurg; 2016 Apr; 124(4):998-1007. PubMed ID: 26452121
[TBL] [Abstract][Full Text] [Related]
7. Molecular Predictors of Long-Term Survival in Glioblastoma Multiforme Patients.
Lu J; Cowperthwaite MC; Burnett MG; Shpak M
PLoS One; 2016; 11(4):e0154313. PubMed ID: 27124395
[TBL] [Abstract][Full Text] [Related]
8. Glioblastoma multiforme (GBM) in the elderly: initial treatment strategy and overall survival.
Glaser SM; Dohopolski MJ; Balasubramani GK; Flickinger JC; Beriwal S
J Neurooncol; 2017 Aug; 134(1):107-118. PubMed ID: 28527010
[TBL] [Abstract][Full Text] [Related]
9. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
[TBL] [Abstract][Full Text] [Related]
10. Long-term survival of patients with glioblastoma multiforme (GBM).
Smoll NR; Schaller K; Gautschi OP
J Clin Neurosci; 2013 May; 20(5):670-5. PubMed ID: 23352352
[TBL] [Abstract][Full Text] [Related]
11. Risk of subsequent cancer among pediatric, adult and elderly patients following a primary diagnosis of glioblastoma multiforme: a population-based study of the SEER database.
Li X; Li Y; Cao Y; Li P; Liang B; Sun J; Feng E
Int J Neurosci; 2017 Nov; 127(11):1005-1011. PubMed ID: 28288541
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: a clinical study in Chinese patients.
Zhang G; Huang S; Zhang J; Wu Z; Lin S; Wang Y
J Neurooncol; 2016 Apr; 127(2):355-62. PubMed ID: 26725096
[TBL] [Abstract][Full Text] [Related]
13. Treatment and survival of patients harboring histological variants of glioblastoma.
Ortega A; Nuño M; Walia S; Mukherjee D; Black KL; Patil CG
J Clin Neurosci; 2014 Oct; 21(10):1709-13. PubMed ID: 24980627
[TBL] [Abstract][Full Text] [Related]
14. Age alone is not a predictor for survival in glioblastoma.
Gately L; Collins A; Murphy M; Dowling A
J Neurooncol; 2016 Sep; 129(3):479-485. PubMed ID: 27406585
[TBL] [Abstract][Full Text] [Related]
15. Which glioblastoma multiforme patient will become a long-term survivor? A population-based study.
Scott JN; Rewcastle NB; Brasher PM; Fulton D; MacKinnon JA; Hamilton M; Cairncross JG; Forsyth P
Ann Neurol; 1999 Aug; 46(2):183-8. PubMed ID: 10443883
[TBL] [Abstract][Full Text] [Related]
16. Glioblastoma in adolescents and young adults: An age-based comparative study from Jordan over a 17-year period.
Alhalaseh YN; Abdulelah ZA; Abu-Shanab A; Armouti AO; Amarin JZ; Mansour R; Sultan H; Al-Hussaini M
Cancer Epidemiol; 2021 Aug; 73():101948. PubMed ID: 33975256
[TBL] [Abstract][Full Text] [Related]
17. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
[TBL] [Abstract][Full Text] [Related]
18. Long-term survivors of glioblastoma: a closer look.
Gately L; McLachlan SA; Philip J; Ruben J; Dowling A
J Neurooncol; 2018 Jan; 136(1):155-162. PubMed ID: 29079955
[TBL] [Abstract][Full Text] [Related]
19. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
20. Risk of second malignancies in patients with early-stage classical Hodgkin's lymphoma treated in a modern era.
LeMieux MH; Solanki AA; Mahmood U; Chmura SJ; Koshy M
Cancer Med; 2015 Apr; 4(4):513-8. PubMed ID: 25620577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]